Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Leon Berard
With
The Biostatistics and Therapy Evaluation Unit
Institut National de la Santé Et de la Recherche Médicale, France
Ligue contre le cancer, France
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women \> 18 years old
Metastatic breast cancer HR+ (Hormone Receptor positive), HER2/neu negative (Human Epidermal Growth Factor Receptor-2)
ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤2
Eligible to an hormonotherapy treatment combined to an mTOR (mammalian Target Of Rapamycin) inhibitor (i.e. SPC (Summary of Product Characteristics) modalities)
Measurable disease according to RECIST 1.1 (Response Evaluation Criteria In Solid Tumors)
Not receiving the non-authorized concomitant treatments
Patient should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed.
Patients must be covered by a medical insurance
You may not be if
BMI\>30
All dysimmune disease, history of transplantation or immunosuppressive therapy or corticotherapy
All chronic inflammatory diseases
Last chemotherapy \< 6 months
Corticotherapy \<1 year and more than 1 month
Restrictive diet ≤3 months before inclusion
Clareo Health | Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)
